Astellas Pharma Inc. has been experiencing a range of corporate activities and market movements. A few years back, the company saw its shares fall 26%, and even after a recent 6.5% gain, they are still down. However, the company has seen significant development in its operations, particularly with its aggressive
growth strategy. Past activities include securing a license agreement for a gene therapy with AviadoBio and obtaining an expanded label by the U.S. FDA for its drug IZERVAY, intended for geographic atrophy. Furthermore, Astellas Pharma recently opened a new Life Sciences Center in Cambridge, Massachusetts, intended to
accelerate the discovery of breakthrough therapies. Despite some hardships, including an employee indictment in China and the announcement of significant restructuring, the company continues to push forward. For instance, they recently won patent validity for their bladder drug, Myrbetriq, against Zydus. Moreover, Astellas is focusing on its drug discovery platform, potential collaboration with YASKAWA on cell therapy manufacturing, and new partnerships concentrated on driving sustainability. Despite these promising developments, some analysts advise caution ahead of the company's next dividend payment.
Astellas Pharma Inc. News Analytics from Wed, 31 May 2017 16:44:13 GMT to Sat, 19 Apr 2025 23:26:29 GMT -
Rating -1
- Innovation 5
- Information 8
- Rumor 2
